First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation ...

Bennu samples reveal biological sugars, a strange, gum-like material, and ancient stardust that shed light on the early solar ...

Health-care companies rose amid optimism about earnings growth in the sector. Shares of Danish obesity drug maker Novo Nordisk rose by 5.8%, recouping some recent losses. Rival Eli Lilly rose modestly ...

Shares of Azenta rose on Wednesday after the company's board of directors approved the repurchase of up to $250 million of common stock. Shares rose 5% to $37.23, though are down 20% year-to-date. The ...

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market ...

Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which ...

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...

A major earnings reset and fresh fund interest could mark a turning point for this formerly high-flying life-sciences stock.

Azenta shows strong organic growth, margin expansion, $1B+ asset value, rebounding sales multiples, and positive FY26 guidance. See why AZTA stock is a hold.

Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 14.9% in the afternoon session after it reported third-quarter 2025 results that featured better-than-expected revenue and profitability. ...

Life sciences company Azenta (NASDAQ:AZTA) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.5% year on year to $159.2 million. Its non-GAAP profit of $0.19 per ...